Immunology
🇺🇸 FDAFDA news and analysis for pharmaceutical BD, investment, and market access
Gain critical insights into global immunology drug development, market trends, and regulatory landscapes. Inform your pharma BD and investment strategy.
Showing 1–12 of 50 articles
Quick answer
NovaPharmaNews Immunology hub for FDA covers 50 published articles — news and analysis for pharma BD, investors, and market access teams. Browse related topics below or explore companies, pipeline, and events linked from each story.
AbbVie Cerevel acquisition closes in $8.7B neuroscience deal
AbbVie closes $8.7B Cerevel deal as neuroscience pipeline expands
Cellenkos Receives FDA Clearance for CK0802 Phase 2a Trial in Steroid-Refractory GVHD
Cellenkos Receives FDA Clearance for CK0802 Phase 1b/2a Trial in Steroid-Refractory GVHD
Takeda's TAK-881 Shows Positive Phase 2/3 Results for Primary Immunodeficiency Disease Treatment
InflaRx Izicopan Shows Low Reactive Metabolite Formation in Liver Safety Study
InflaRx Reports Favorable Safety Profile for Izicopan in Liver Metabolism Study
UCB Acquires Candid Therapeutics in Major Autoimmune Drug Development Deal
NIKTIMVO (Axatilimab) Approved in Australia as First-in-Class Chronic Graft-Versus-Host Disease Treatment
Atara Biotherapeutics Receives FDA Complete Response Letter for EBVALLO Cancer Treatment, Faces Securities Class Action
FDA Approves Incyte's Jakafi XR Extended-Release Tablets for Myelofibrosis, Polycythemia Vera, and GVHD Treatment
MRM Health's MH002 Receives FDA Fast Track Designation for Ulcerative Colitis Treatment
Frequently asked questions
How often is this topic updated?
New articles are published continuously as regulatory, clinical, and commercial signals break. Use the content-type filters for latest news vs in-depth analysis.
Where does this coverage come from?
Editorial intelligence combines FDA openFDA, ClinicalTrials.gov, SEC EDGAR, congress calendars, and analyst reporting. See our data sources policy for attribution.